SVF
Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Sprayable bioadhesive microcarriers loaded with Tβ4-Engineered ADSC exosomes for diabetic wound healing.

Ding Y., Huang D., Zhao Z., Feng H., Zhou S., Qian D.

Laboratory Study on Diabetic Foot, Chronic Wound, published in Bioact Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Bioact Mater (2026)
Country
China
Reported sample size
—
Source database
PubMed
PMID
42383202
DOI
10.1016/j.bioactmat.2026.06.024

Abstract (original English)

Stem cell-derived therapeutics show strong potential to recalibrate diabetic wound immunity, yet their stability, retention, and practical usability remain major barriers to effective application. Here, we report a novel microcarrier platform loaded with thymosin β4 (Tβ4)-overexpressing stem cell-derived exosomes for a sprayable diabetic wound dressing. Adipose-derived stem cells (ADSCs) were genetically engineered to overexpress Tβ4, generating potent immunoregulatory exosomes that were efficiently encapsulated into uniform, micron-scale hydrogel microcarriers via microfluidic fabrication and further functionalized with a mesoporous polydopamine (mPDA) coating to enhance wet adhesion and tissue retention. The resulting EXOs Tβ4 /mPDA@MS system stabilizes the exosome payload and enables convenient spray-based wound administration. These microcarriers provide sustained, localized exosome release, significantly enhance macrophage efferocytosis, suppress inflammatory signaling, and accelerate wound repair in diabetic models. Thus, our engineered, sprayable, and adhesive microcarrier platform offers a stable, minimally invasive, and clinically adaptable strategy for advancing stem cell-derived exosome therapies in chronic diabetic wound repair.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Diabetic FootChronic Wound
View on PubMedDOI

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

View all: topic “sprayable bioadhesive microcarriers”View all: author dingView all: year 2026

Related research